PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000975820.37624.bc |
| _version_ | 1797280761150177280 |
|---|---|
| author | Lihua Qiu Tingyu Wang Xiuhua Sun Hang Su Junning Cao Zhi-Ming LI Yuqin Song LI Zhang Dengju LI Huijing Wu Wei Zhang Junmin LI Keshu Zhou Hui Zhou Yu Yang Zhifeng LI Hong Cen Zhen Cai Zhihui Zhang Weijun Fu Jie Jin Fei LI Weixin Wu Xuekui Gu Weiliang Zhu Lihong Liu Zengjun LI Shuhua Yi Lugui Qiu |
| author_facet | Lihua Qiu Tingyu Wang Xiuhua Sun Hang Su Junning Cao Zhi-Ming LI Yuqin Song LI Zhang Dengju LI Huijing Wu Wei Zhang Junmin LI Keshu Zhou Hui Zhou Yu Yang Zhifeng LI Hong Cen Zhen Cai Zhihui Zhang Weijun Fu Jie Jin Fei LI Weixin Wu Xuekui Gu Weiliang Zhu Lihong Liu Zengjun LI Shuhua Yi Lugui Qiu |
| author_sort | Lihua Qiu |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:45:51Z |
| format | Article |
| id | doaj.art-00ba39c9e3dd4c03ada9c800daf17187 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:45:51Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-00ba39c9e3dd4c03ada9c800daf171872024-03-03T06:25:43ZengWileyHemaSphere2572-92412023-08-017e37624bc10.1097/01.HS9.0000975820.37624.bc202308003-02129PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIALLihua Qiu0Tingyu Wang1Xiuhua Sun2Hang Su3Junning Cao4Zhi-Ming LI5Yuqin Song6LI Zhang7Dengju LI8Huijing Wu9Wei Zhang10Junmin LI11Keshu Zhou12Hui Zhou13Yu Yang14Zhifeng LI15Hong Cen16Zhen Cai17Zhihui Zhang18Weijun Fu19Jie Jin20Fei LI21Weixin Wu22Xuekui Gu23Weiliang Zhu24Lihong Liu25Zengjun LI26Shuhua Yi27Lugui Qiu281 Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Department of Lymphoma, Tianjin, China2 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin, China3 The Second Hospital of Dalian Medical University, Department of Medical Oncology, Dalian, China4 The Fifth Medical Center of PLA General Hospital, Department of Lymphoma, Senior Department of Hematology, Beijing, China5 Fudan University Shanghai Cancer Center, Department of Medical Oncology, Shanghai, China6 Sun Yat-sen University Cancer Center, Department of Medical Oncology, Guangzhou, China7 Peking University School of Oncology, Beijing Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Beijing, China8 West China Hospital, Sichuan University, Department of Hematology, Chengdu, China9 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Department of Hematology, Wuhan, China10 Hubei Cancer Hospital, Department of Medical Oncology, Wuhan, China11 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Department of Hematology, Beijing, China12 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai, China13 The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Department of Hematology, Zhengzhou, China14 Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Department of Lymphoma & Hematology, Changsha, China15 Fujian Provincial Cancer Hospital, The Affiliated Tumor Hospital of Fujian Medical University, Department of Lymphoma and Head and Neck Cancer, Fuzhou, China16 The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Department of Hematology, Xiamen, China17 Guangxi Medical University Affiliated Cancer Hospital, Department of Haematology/Oncology and Paediatric Oncology, Nanning, China18 he First Affiliated Hospital, Zhejiang University School of Medicine, Department of Hematology, Hangzhou, China19 Sichuan Cancer Hospital and Institute, Department of Medical Oncology, Chengdu, China20 Shanghai Fourth People’s Hospital, School of Medicine, Tongji University, Department of Hematology, Shanghai, China18 he First Affiliated Hospital, Zhejiang University School of Medicine, Department of Hematology, Hangzhou, China21 The First Affiliated Hospital of Nanchang University, Department of Hematology, Nanchang, China22 Zhongshan Hospital, Xiamen University, Department of Internal Medicine and Oncology, Xiamen, China23 The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Department of Hematology, Guangzhou, China24 Zhujiang Hospital of Southern Medical University, Department of Oncology, Guangzhou, China25 The Fourth Hospital of Hebei Medical University, Department of Hematology, Shijiazhuang, China2 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin, China2 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin, China2 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin, Chinahttp://journals.lww.com/10.1097/01.HS9.0000975820.37624.bc |
| spellingShingle | Lihua Qiu Tingyu Wang Xiuhua Sun Hang Su Junning Cao Zhi-Ming LI Yuqin Song LI Zhang Dengju LI Huijing Wu Wei Zhang Junmin LI Keshu Zhou Hui Zhou Yu Yang Zhifeng LI Hong Cen Zhen Cai Zhihui Zhang Weijun Fu Jie Jin Fei LI Weixin Wu Xuekui Gu Weiliang Zhu Lihong Liu Zengjun LI Shuhua Yi Lugui Qiu PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL HemaSphere |
| title | PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL |
| title_full | PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL |
| title_fullStr | PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL |
| title_full_unstemmed | PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL |
| title_short | PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL |
| title_sort | pb2272 pi3kδ inhibitor linperlisib for patients with relapsed or refractory follicular lymphoma subgroup analysis of a phase 2 trial |
| url | http://journals.lww.com/10.1097/01.HS9.0000975820.37624.bc |
| work_keys_str_mv | AT lihuaqiu pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT tingyuwang pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT xiuhuasun pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT hangsu pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT junningcao pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT zhimingli pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT yuqinsong pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT lizhang pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT dengjuli pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT huijingwu pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT weizhang pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT junminli pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT keshuzhou pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT huizhou pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT yuyang pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT zhifengli pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT hongcen pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT zhencai pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT zhihuizhang pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT weijunfu pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT jiejin pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT feili pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT weixinwu pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT xuekuigu pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT weiliangzhu pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT lihongliu pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT zengjunli pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT shuhuayi pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT luguiqiu pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial |